Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Anti-Obesity Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 12.3% during the forecast period.
This report presents the market size and development trends by detailing the Anti-Obesity Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Anti-Obesity Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Anti-Obesity Drugs industry and will help you to build a panoramic view of the industrial development.
Anti-Obesity Drugs Market, By Type:
Prescription Drugs
OTC Drugs
Anti-Obesity Drugs Market, By Application:
6-18 Callant
18-30 Adult
30-60Middle-Aged
Others
Some of the leading players are as follows:
F Hoffmann-La Roche AG
Merck
Alizyme
Pfizer
AstraZeneca
Bayer AG
GlaxoSmithKline
Eisai
Boehringer Ingelheim
Arena Pharmaceuticals
Novo Nordisk AS
F.Hoffmann-La Roche
Norgine
Shionogi
Novo Nordisk
Vivus
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Anti-Obesity Drugs Market: Technology Type Analysis
-
4.1 Anti-Obesity Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Anti-Obesity Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Prescription Drugs
4.3.2 OTC Drugs
5 Anti-Obesity Drugs Market: Product Analysis
-
5.1 Anti-Obesity Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Anti-Obesity Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Anti-Obesity Drugs Market: Application Analysis
-
6.1 Anti-Obesity Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Anti-Obesity Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 6-18 Callant
6.3.2 18-30 Adult
6.3.3 30-60Middle-Aged
6.3.4 Others
7 Anti-Obesity Drugs Market: Regional Analysis
-
7.1 Anti-Obesity Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Anti-Obesity Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 F Hoffmann-La Roche AG
9.1.1 F Hoffmann-La Roche AG Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Merck
9.2.1 Merck Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Alizyme
9.3.1 Alizyme Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Pfizer
9.4.1 Pfizer Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 AstraZeneca
9.5.1 AstraZeneca Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Bayer AG
9.6.1 Bayer AG Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 GlaxoSmithKline
9.7.1 GlaxoSmithKline Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Eisai
9.8.1 Eisai Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Boehringer Ingelheim
9.9.1 Boehringer Ingelheim Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Arena Pharmaceuticals
9.10.1 Arena Pharmaceuticals Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Novo Nordisk AS
9.11.1 Novo Nordisk AS Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 F.Hoffmann-La Roche
9.12.1 F.Hoffmann-La Roche Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Norgine
9.13.1 Norgine Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Shionogi
9.14.1 Shionogi Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Novo Nordisk
9.15.1 Novo Nordisk Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Vivus
9.16.1 Vivus Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
The List of Tables and Figures (Totals 84 Figures and 145 Tables)
Figure Prescription Drugs Anti-Obesity Drugs market, 2015 - 2026 (USD Million)
Figure OTC Drugs Anti-Obesity Drugs market, 2015 - 2026 (USD Million)
Figure 6-18 Callant market, 2015 - 2026 (USD Million)
Figure 18-30 Adult market, 2015 - 2026 (USD Million)
Figure 30-60Middle-Aged market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Anti-Obesity Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Anti-Obesity Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Anti-Obesity Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Anti-Obesity Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Anti-Obesity Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Anti-Obesity Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Anti-Obesity Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Anti-Obesity Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table F Hoffmann-La Roche AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Alizyme Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eisai Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Arena Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novo Nordisk AS Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F.Hoffmann-La Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Norgine Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Shionogi Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Vivus Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
